HomeMarkets overviewSharesMoonLake Immunotherapeutics

Trade MoonLake Immunotherapeutics - MLTX CFD

19.2+1.91%
The chart shows the MLTX stock price data over the last 1 day, with a current price of 19.2, a high of 19.24, and a low of 18.48.
Low: 18.48High: 19.24
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.14
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.021512 %
(-$0.43)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.02151%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.00071 %
(-$0.01)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.00071%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity0.1
Margin50.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close18.82
Open18.55
1-Year Change-61.96%
Day's Range18.48 - 19.24

Trade MoonLake Immunotherapeutics - MLTX

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotech developing nanobody therapies for inflammatory diseases. Its lead candidate, sonelokimab, is in Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis. With fast-track potential and a differentiated platform, MoonLake is a high-momentum biotech name in immunology.

Latest shares articles

Stellantis stock forecast: Wayve-Uber robotaxi deal
Stellantis is a Milan-listed automaker, with recent developments including a non-binding robotaxi agreement with Wayve and Uber. Explore third-party STLAM price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:11, 25 June 2026
AMD stock forecast: Advancing AI event, Q2 earnings
AMD is a US semiconductor company whose shares have drawn attention from AI data centre demand and its upcoming ‘Advancing AI 2026’ event in July. Explore third-party Advanced Micro Devices price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:32, 23 June 2026
Federal Reserve Building
Market Mondays: Warsh’s first Fed meeting sets the tone for a new era
Markets adapt to the new Federal Reserve under Warsh leadership as he offers little information in regards to forward guidance.
11:34, 22 June 2026
Stellantis stock forecast: FaSTLAne 2030 plan
Stellantis is a global automaker whose 2026 outlook is shaped by its FaSTLAne 2030 plan, Q1 shipment growth and higher US tariffs on EU auto imports. Explore third-party STLAM price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:22, 16 June 2026
Related News
Public TechnologiesEurope
20:11 (UTC), 2 July 2026
MoonLake CEO Jorge Santos da Silva sells 47,775 shares for $956,918.25
Reuters NewsEurope
13:41 (UTC), 24 June 2026
MoonLake Immunotherapeutics slides after $200 mln share sale
Public TechnologiesEurope
03:13 (UTC), 24 June 2026
MoonLake Immunotherapeutics prices upsized public offering at USD 200 million
Reuters NewsEurope
03:09 (UTC), 24 June 2026
Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share
Public TechnologiesEurope
03:08 (UTC), 24 June 2026
MoonLake Immunotherapeutics prices upsized public offering at USD 200 million
Public TechnologiesEurope
20:01 (UTC), 23 June 2026
MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60
Reuters NewsEurope
21:33 (UTC), 22 June 2026
MoonLake Immunotherapeutics falls on planned $150 mln equity raise
Public TechnologiesEurope
20:01 (UTC), 22 June 2026
MoonLake Immunotherapeutics plans USD 150 million follow-on share offering
GlobeNewswireEurope
20:01 (UTC), 22 June 2026
MoonLake Immunotherapeutics Announces Proposed Public Offering

User feedback and ratings

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start trading